(Reuters) – Merck & Co Inc said on Tuesday it had tied up with five generic drugmakers in India to expand access to molnupiravir, an experimental antiviral COVID-19 therapy it is developing with Ridgeback Biotherapeutics.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Ramakrishnan M.)
